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Abstract
Aims/hypothesis We aimed to identifymicroRNAs (miRNAs)
under transcriptional control of the HNF1β transcription
factor, and investigate whether its effect manifests in serum.
Methods The Polish cohort (N=60) consisted of 11 patients
withHNF1B-MODY, 17 withHNF1A-MODY, 13 withGCK-
MODY, an HbA1c-matched type 1 diabetic group (n=9) and
ten healthy controls. Replication was performed in 61
clinically-matched British patients mirroring the groups in
the Polish cohort. The Polish cohort underwent miRNA serum
level profiling with quantitative real-time PCR (qPCR) arrays
to identify differentially expressed miRNAs. Validation was
performed using qPCR. To determine whether serum content
reflects alterations at a cellular level, we quantified miRNA
levels in a human hepatocyte cell line (HepG2) with small
interfering RNA knockdowns of HNF1α or HNF1β.
Results Significant differences (adjusted p<0.05) were noted
for 11 miRNAs. Five of them differed between HNF1A-
MODY and HNF1B-MODY, and, amongst those, four
(miR-24, miR-27b, miR-223 and miR-199a) showed
HNF1B-MODY-specific expression levels in the replication
group. In all four cases the miRNA expression level was lower
inHNF1B-MODY than in all other tested groups. Areas under
the receiver operating characteristic curves ranged from 0.79
to 0.86, with sensitivity and specificity reaching 91.7%
(miR-24) and 82.1% (miR-199a), respectively. The cellular
expression pattern of miRNA was consistent with serum
levels, as all were significantly higher in HNF1α- than
in HNF1β-deficient HepG2 cells.
Conclusions/interpretation We have shown that expression of
specific miRNAs depends on HNF1β function. The impact of
HNF1β deficiency was evidenced at serum level, making
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miRNA microRNA
qPCR Quantitative real-time PCR
siRNA Small interfering RNA
TF Transcription factor
Introduction
Monogenic diabetes is a heterogeneous group of diseases
caused by loss of function of single genes important for
pancreatic beta cell function, survival or peripheral insulin
action [1, 2]. Whereas each of the monogenic defects is
fairly uncommon, together they are aetiological factors in
potentially up to 2% of patients with diabetes, amounting
to a prevalence of ~110 per million [3, 4]. HNF1B-MODY
(or MODY5 [5]), is caused by dominant mutations of the
gene encoding hepatocyte nuclear factor 1 beta (HNF1β),
a POU-family transcription factor (TF) necessary for
proper development of pancreatic beta cells and kidneys
[6]. We hypothesised that hepatocyte nuclear factor 1 alpha
(HNF1α) and HNF1β, as two structurally similar TFs, may
regulate not only different genes, as shown in earlier gene
expression studies [7], but also microRNAs (miRNAs).
Expression of miRNAs is regulated by TFs, either indirectly
as passengers of stimulated gene expression (in the case of
miRNA sequences located within introns) or directly through
TF binding to cis regulatory regions [8]. Experimental data in
a mouse model of HNF1β knockdown presented by Kornfeld
et al [9] showed that expression of multiple hepatic miRNAs
depends on HNF1β function. If miRNA expression profiles
vary at cellular levels, one could assume that their serum
levels are also altered, as serummiRNAs originate from active
secretion by cells or as a consequence of cell death [10]. This
prompted us to search for an miRNAwhose expression would
be specifically altered in HNF1B-MODY. If indeed an
HNF1B-MODY-specific miRNA expression pattern could
be identified, it could bolster the current diagnostic strategies
of monogenic diabetes, which involve the application of
statistical tools to stratify candidates for genetic screening
[11, 12], or biomarkers [13–15]. The objective of our study
was to identify miRNAs under the transcriptional control
of HNF1β or HNF1α and assess the potential of such
miRNAs as biomarkers of monogenic diabetes.
Methods
The study was approved by the Institutional Bioethics
Committee at the Medical University of Lodz (no. RNN/
18/12/KE 2012). All patients gave their informed consent
for participation in the study; for children, parental approval
was obtained instead.
Group recruitment
The studied population consisted of two groups: the primary
group and the replication group. Patients in the primary group
were recruited from the Polish Registry of Monogenic
Diabetes [4, 16]. The primary group was planned to include
all known Polish patients withHNF1B-MODYwith available
serum samples, and four comparative groups: HNF1A-
MODY, GCK-MODY (involving the gene encoding glucoki-
nase [GCK]), type 1 diabetes and healthy controls. The two
HNF1-MODY groups consisted of: 11 patients with HNF1B-
MODY and 17 patients with HNF1A-MODY matched
(1:1.5 ratio) for age, sex, BMI and HbA1c levels. Three control
groups were used: ten age- and sex-matched healthy indi-
viduals, 13 age- and sex-matched patients with GCK-MODY
(to control for hyperglycaemia with preserved pancreatic islet
beta cells) and nine HbA1c-matched patients with type 1
diabetes positive for at least two autoantibodies directed
against pancreatic beta cells, and undetectable C-peptide
levels at onset of diabetes.
The UK group (replication group) was recruited from the
UK MODY registry [3] overseen by the Diabetes Research
department and the Centre for Molecular Genetics at the
University of Exeter Medical School and Royal Devon and
Exeter Hospital. We selected patients with HNF1B-MODY
with available serum samples, a matched HNF1A-MODY
group and the three other comparative groups matched as
above. Details about causative mutations in the three
MODY groups of Polish and UK patients are provided in
Table 1 of the electronic supplementary material (ESM).
Molecular methods
Serum miRNA profiling and measurements Fasting serum
samples were used in the study. We used real-time PCR arrays
with locked nucleic acid-containing primers (miRCURY
LNA; Exiqon, Copenhagen, Denmark) for serum profiling,
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as our hypothesis assumed a drop in miRNA expression,
which necessitated high, detectable levels in healthy individ-
uals. Exiqon real-time PCR human miRNA arrays A and B
quantify expression of 752 miRNAs detectable in serum and
provide very high sensitivity and reproducibility in compari-
son with other methods [17]. A standard protocol for circulat-
ing miRNA extraction, purification and analysis was used as
in our previous study on circulating miRNA biomarkers [18].
In the replication group we quantified expression of miRNAs
that were shown to be differentially expressed in the primary
group. Quantitative real-time PCR (qPCR) was performed
using Exiqon’s PCR miRNA-specific primer sets.
The reference miRNA for normalisation of the profiling
assay was selected using the NormFinder algorithm [19]; the
most stable reference was found to be the average expression
level of assays detected in all samples. Thirteen such miRNAs
were identified and their average threshold cycles (Ct) were
used as the reference for normalisation performed using the
formulaΔCt ¼ Ct referenceð Þ  Ct miRNAof interestð Þ, which
provides a higher value for higher miRNA expression,
facilitating its use and interpretation as a biomarker. For
the replication group, we used the average expression of
the three miRNAs (miR-142-3p, miR-126-3p, miR-16-5p)
for normalisation. These miRNAs were selected out of the
13 used for normalisation in the primary experiment on
the basis of universal and stable transcription and lack of
significant differences between the five compared groups.
A re-analysis of the primary group data with normalisation
towards these three miRNAs yielded convergent results to
normalisation against average expression level (data not
shown). Details on isolation, reverse transcription and qPCR
reactions in the primary group are shown in ESM Methods/
Serum miRNA extraction, profiling and measurements.
Details about the miRNA expression study in the replication
group are shown in ESM Methods/miRNA real-time qPCR
assays in the replication group.
Silencing of HNF1B and HNF1A: cell line experiment A
human hepatocyte (HepG2) cell line was grown in an
incubator at 37°C in 5% CO2 in DMEM (Sigma-Aldrich,
Taufkirchen, Germany), supplemented with 10% fetal bovine
serum (10270; Gibco, Darmstadt, Germany), 2 mmol/l
L-glutamine (Gibco), 1 mmol/l sodium pyruvate (Sigma-
Aldrich), 100 U/ml penicillin, and 100 μg/ml streptomycin
(Gibco), until 80–90% confluence was reached. For silencing
of HNF1A and HNF1B expression, the following small
interfering RNAs (siRNAs) were used (all from Ambion,
Austin, TX, USA): siRNA specific for HNF1α—s13868
(siRNA1a), s13869 (siRNA2a), s13870 (siRNA3a);
siRNA specific for HNF1β—s13871 (siRNA1b), s13872
(siRNA2b).
A Nucleofector technology system (Amaxa Cell Line
Nucleofector VCA-1003; Lonza, Basel, Switzerland) was
used to transfect siRNA into the HepG2 cells; details on the
procedure are listed in ESM Methods/Silencing of HNF1B
and HNF1A genes—cell line experiment.
Expression of HNF1A and HNF1B
and HNF-dependent miRNAs
Total RNA was isolated from HepG2 cell pellet (106 cells)
using an RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. Coding DNA
(cDNA; reverse-transcribed from RNA) was synthesised
with High Capacity cDNA Reverse Transcription Kits
(Applied Biosystems, Foster City, CA, USA). HNF1A
and HNF1B mRNA levels were quantified using qPCR
with the Mx3005P QPCR System (Agilent Technologies,
Santa Clara, CA, USA). Western blots were used to confirm
efficient HNF1α and HNF1β silencing at the protein level.
Expression of miRNAs differentially expressed in HNF1A-
and HNF1B-MODY was quantified using qPCR in cell lysate
and culture medium. Measurement of miRNA expression was
done similarly to the serum part of the study using TaqMan
miRNA Assays (Applied Biosystems). All reactions were
run in triplicate. U6 small nuclear RNA was used as an
endogenous control (Applied Biosystems). In-depth descrip-
tion of molecular methods is provided in ESM Methods/
Expression of HNF1A and HNF1B and HNF-dependent
miRNAs.
Statistical analysis
We used linear discriminant analysis for initial group separa-
tion. One-way ANOVAwas performed to screen miRNAs for
those showing differential expression between the tested
groups. The Benjamini–Hochberg correction was used to con-
trol the false discovery rate. All miRNAs with a p value and
false discovery rate below 0.05 were compared using Tukey’s
post hoc test to confirm between-group differences.
Covariate-adjusted comparisons in the UK group were per-
formed using analysis of covariance (ANCOVA) with
Tukey’s post hoc test. These comparisons were adjusted for
patients’ sex, age, BMI and HbA1c levels. A p value below
0.05 was considered statistically significant. Categorical vari-
ables were compared using the χ2 test. Statistica version 12.5
(StatSoft, Tulsa, OK, USA) and MultiExperiment Viewer
(Dana Farber Cancer Institute, Boston, MA, USA) were used
for statistical analyses. Receiver operating characteristic
curves were created for differentially expressed miRNA that
replicated in both cohorts. A multivariate classifier model was
created using logistic regression. In order to retain the full
sample size of the multivariate model, in the primary group
missing expression values were imputed with average
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expression levels of a specific miRNA in the whole
dataset. No imputation was necessary in the replication
group, as all patients had detectable expression levels of the
differentially expressed miRNAs. Gene-set enrichment anal-
yses were conducted according to Subramanian et al [20].
Analysis of HNF1α and HNF1β binding sites in upstream
regions of the analysed miRNAs was performed using the
PROMO3 tool, linked to the TRANSFAC database [21].
Results
The clinical characteristics of the primary group are presented
in Table 1. No significant differences in sex and age distri-
bution were noted between controls and all three MODY
groups (p=0.10 and p=0.19, respectively). Patients with type
1 diabetes did not differ in HbA1c level compared with those
in the three MODY groups (p = 0.11). No significant
differences were noted in BMI values (p=0.10). Expression
of the studied miRNAs, presented as ΔCt values, is reported
in ESMTable 2. A total of 83 miRNAs were present in at least
five sera from each group (ESM Table 3). Linear discriminant
analysis showed efficient discrimination between groups,
using miRNA profiles with a potential for distinguishing
HNF1A-MODY and HNF1B-MODY groups (Fig. 1a).
Significance criterion was met by 11 distinct miRNAs:
miR-223, miR-24, miR-99b, miR-423, miR-92a, miR-27b,
miR-23a, miR-199a, miR-101, miR-145 and miR-32; these
are presented on a hierarchical cluster heatmap in Fig. 1b.
Among the 11 differentially expressed miRNAs (significant
in ANOVA), eight differed significantly between HNF1B-
MODY and at least one of the other groups (miR-32,
miR-223, miR-23a, miR-199a, miR-27b, miR-24, miR-145
and miR-423; ESM Table 3). Expression levels (presented
as ΔCts) of those miRNAs are presented in Fig. 1c–j. The
most striking differences were found between the HNF1B-
MODY and HNF1A-MODY groups, evidenced by lower
expression levels of miR-223, miR-24, miR-27b and
miR-199a in the former. Only miR-32 showed higher
expression in HNF1B than in HNF1A-MODY. Another
notable finding was miR-145, which showed significantly
higher expression in controls than in all other groups, hinting
at its utility as a marker for hyperglycaemia or beta cell
impairment. Significant differences between the GCK-MODY,
type 1 diabetes and control groups were less numerous,
with miR-24 showing higher expression in controls than
in patients with type 1 diabetes (adjusted p = 0.0060);
miR-24, along with miR-23a, miR-145 and miR-99b, also
showed significantly lower expression levels inGCK-MODY
than in controls (p = 0.0011, p = 0.0103, p = 0.0042 and
p= 0.0236, respectively). No significant differences were
noted between the GCK-MODYand type 1 diabetic groups
(ESM Table 3).
Having established which of the circulating miRNAs seem
to be dependent on HNF1A or HNF1B defects, we set about
replicating the findings in our UK group of patients with
Table 1 Clinical characteristics of the studied groups
Study group HNF1A-MODY HNF1B-MODY GCK-MODY Type 1 diabetes Controls
Polish patients (primary group)a
Sex, M/F 4/13 5/6 8/5 3/6 2/8
Age at examination, years 32.00 (21.00–49.00) 25.44 (13.44–37.81) 20.74 (18.14–24.38) 14.18 (9.79–16.33) 28.2 (23.04–30.06)
BMI, kg/m2 20.00 (18.70–23.80) 23.30 (19.60–24.81) 23.09 (21.83–24.65) 18.00 (16.10–19.20) 22.95 (21.88–26.72)
Duration of diabetes, years 11.00 (7.00–17.00) 1.01 (0.27–3.41) 1.16 (0.38–10.79) 0.50 (0.46–3.53) NA
HbA1c, % 6.50 (5.30–8.70) 5.90 (5.00–6.30) 6.41 (6.30–6.50) 6.80 (6.40–10.50) NA
HbA1c, mmol/mol 48 (34–72) 41 (31–45) 47 (45–48) 51 (46–91) NA
UK patients (replication group)b
Sex, M/F 7/11 9/3 4/6 3/8 1/9
Age at examination, years 30.50 (21.00–40.00) 37.50 (21.50–42.50) 21.00 (19.00–25.00) 17.00 (15.00–29.00) 26.00 (19.00–30.00)
BMI, kg/m2 22.40 (20.00–24.60) 23.00 (19.07–24.40) 22.80 (21.40–25.10) 21.60 (20.90–25.00) 24.09 (22.41–24.90)
Duration of diabetes, years 1.00 (0.00–18.00 4.00 (0.00–8.00) 1.00 (0.00–1.00) 2.00 (1.00–5.00) NA
HbA1c, % 6.50 (5.80–6.90) 7.30 (6.50–7.70) 6.35 (6.20–6.70) 7.00 (6.40–9.60) NA
HbA1c, mmol/mol 48 (40–52) 53 (48–61) 46 (44–50) 53 (46–81) NA
Data are medians (25–75% percentile values)
a Polish patients (primary group):HNF1A-MODY (n= 17, from 12 families),HNF1B-MODY (n= 11, from six families),GCK-MODY (n= 13, from 13
families), type 1 diabetes (n= 9, from nine families), controls (n = 10, from ten families)
b UK patients (replication group):HNF1A-MODY (n = 18, from 18 families),HNF1B-MODY (n= 12, from 12 families),GCK-MODY (n= 10, from ten
families), type 1 diabetes (n= 11, from 11 families), controls (n= 10, from ten families)
NA, not applicable
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monogenic diabetes (Table 1). In this group, patients with type
1 diabetes were marginally younger than those in the other
groups (p = 0.03 in ANOVA), but pairwise differences
between any of the groups were not significant. Patients with
GCK-MODY showed lower HbA1c levels (p= 0.0314 in
ANOVA), but no significant results were noted in post hoc
comparisons. No differences for BMI (p=0.6320) were noted.
Females were significantly over-represented in the UK
HNF1B-MODY group (p=0.0305).
Within the UK group, five out of 11 differentially
expressed miRNAs showed significant differences in
ANOVA. In all cases, the HNF1B-MODY patients differed
from at least one other group (ESM Table 4). The miRNAs
with the most significant differences in expression levels
mirrored those observed in the primary group: miR-24,
miR-223, miR-27b and miR-199a (Fig. 2). Apart from
miR-223, which correlated negatively with BMI in the type
1 diabetic and HNF1A-MODY groups, no significant correla-
tions were noted for the clinical covariates with miRNA
expression levels (ESM Table 5). Afterwards, we used
ANCOVAmodels to determine whether the miRNA differences
would persist after adjustment for age, sex, BMI and HbA1c.
Significant differences in covariate-adjusted expression
levels were noted for miR-24 (p = 0.0072), miR-223
(p = 0.0184), miR-27b (p = 0.0107) and miR-199a
(p= 0.0435; ESM Fig. 1). In all cases, differences in post
hoc tests were significant between the HNF1A- and
HNF1B-MODY groups. A single patient with HNF1B-
MODY aged ≤13 years was excluded from this analysis,
as his raw BMI value would have been incomparable with
the others. Adjusted expression of miR-423 did not differ
significantly between the four groups of patients with diabetes
(p = 0.3899), which excluded this miRNA from further
analyses. A meta-analysis of effect sizes in the primary
Fig. 1 Serum miRNA profiling in the group of Polish patients with
monogenic diabetes. (a) Linear discriminant analysis of miRNA profiles
in the five compared groups. The axes denote the first three canonical
roots. The five groups are represented by: HNF1B-MODY (pink trian-
gles), HNF1A-MODY (red squares), GCK-MODY (green diamonds),
type 1 diabetes (T1DM, black circles), controls (blue circles). (b)
Hierarchical clustering of 11 miRNAs with significantly different expres-
sion levels between the five studied groups. Red denotes higher levels,
green represents lower levels. Grey squares represent samples without
detectable levels of a given miRNA. Expression levels of: (c) miR-24
ΔCt; (d) miR-223 ΔCt; (e) miR-27b ΔCt; (f) miR-199a ΔCt; (g) miR-
32ΔCt; (h) miR-23a ΔCt; (i) miR-423ΔCt; (j) miR-145 ΔCt. Brackets
are used to connect the groups with significant (p < 0.05) pairwise differ-
ences in post hoc comparisons between HNF1B-MODY and other
groups. A detailed list of all pairwise post hoc tests is provided in ESM
Table 3
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and replication groups performed to evaluate homogeneity
of the observed differences showed convergent, significant
results for miR-24, miR-223, miR-27b and miR-199a in
both groups of patients (ESM Fig. 2).
Afterwards, we measured the impact of siRNA-induced
knockdowns of HNF1α and HNF1β on the expression levels
of miR-24, miR-223, miR-27b and miR-199a in human
hepatocytes (HepG2). We tested three different siRNAs
specific for HNF1α, which decreased HNF1α protein level
by 80%, 52% and 63%, respectively (Fig. 3a), and two
different siRNAs for HNF1β, which decreased the level of
HNF1β by 40% and 42% in HepG2 cells (Fig. 3b). The
reduced gene expression of HNF1A and HNF1B after
siRNA transfections was also confirmed at the level of
mRNA (Fig. 3c). For further experiments we used siRNA1a
and siRNA1b, which showed the highest efficiency for
downregulation of HNF1A and HNF1B, respectively. The
silencing of HNF1A significantly decreased levels of
miR-24, miR-27b and miR-199a, and had no effect on the
miR-223 content in HepG2 cells (Fig. 3d). Downregulation
of HNF1B in HepG2 cells resulted in significant reduction of
all analysed miRNAs, with the highest impact on miR-223
whose level was reduced by almost 99%.
These data suggest that serum levels of miR-24, miR-223,
miR-27b and miR-199a associated with HNF1B dysfunction
might reflect changes in intracellular miRNA profile in the
liver. To test this hypothesis, we tested the cell culture media
for miRNA levels 48 h afterHNF1B silencing in HepG2 cells.
The levels of extracellular miR-223, miR-27b and miR-199a
in HNF1β-deficient HepG2 cells were significantly reduced
compared with controls (Fig. 3e). This suggests that hepa-
tocytes are a likely source of circulating miRNAs respon-
sible for an altered serum miRNA profile in patients with
HNF-related monogenic diabetes.
To ascertain potential pathways linked to the apparent
downregulation of miRNA expression levels, we searched
the miRWalk database [22] for validated targets of the four
HNF1β-dependent miRNAs (Fig. 4a). A detailed list of genes
with validated target sites of the four miRNAs and their
combinations is provided in ESM Table 6. There are three
genes to which all four miRNAs could potentially bind:
AKT1, CCND1 and COX8A. From these three, CCND1 and
AKT1 were determined to be the most likely downstream
effectors of the HNF1β signal through the miRNA network.
To evaluate whether the potential target genes of the four
miRNAs are downregulated in vivo, we performed gene-set
enrichment analysis on an expression microarray dataset that
describes gene expression in mice transfected with an
adenovirus-borne silencer for Hnf1b (GSE42188 in Gene
Expression Omnibus database [9]). miR-24, miR-223,
miR-23 and miR-199a show 100% conservation of seed
region sequences between humans and mice [23]. We com-
posed a gene-set of eight target genes, all shown to have
validated miRNA binding sites for at least three of the four
HNF1β-dependent miRNAs: Akt1, Fasn, Cox8a, Dicer1,
Eif2c2 (also known as Ago2), Pik3ca andCcnd1 (ESMTable 6).
This gene-set showed significant upregulation (p= 0.036)
after Hnf1b silencing (Fig. 4b, c), thus supporting our claim
that the downregulation of miRNAs due to loss of the HNF1β
signal may result in upregulation of critical biological
Fig. 2 Comparisons of serum
miRNA levels in the UK group:
(a) miR-24; (b) miR-223; (c)
miR-27b; (d) miR-199a. Brackets
are used to connect the groups
with significant (p < 0.05)
pairwise differences; †p= 0.07;
exact p values are shown in ESM
Table 4
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pathways. Details of the positions of the eight tested genes in
GSEA (www.broad.mit.edu/gsea [20, 24], accessed 10
October 2015) are shown in ESM Table 7. Afterwards, using
the TRANSFAC database, we screened 1,500 bp-long
upstream genomic regions of the four miRNAs for binding
sites of HNF1α and HNF1β. All four miRNAs had such sites
(Fig. 4d, ESM Table 8). HNF1β binding sites were the most
prevalent in the case of miR-223, which correlated with its
having the greatest reduction in expression in the cell line
experiments.
Finally, we examined the diagnostic potential of the four
miRNAs. The cut-off values were calculated for the
miRNAof interest
average of three referencemiRNAs ratios. All four miRNAs showed
biomarker potential, with AUC values reaching or exceeding
0.8 (Table 2). We also analysed how the established cut-offs
separated the HNF1B- from the HNF1A-MODY groups
(Table 2). To finish, we created a multivariable logistic
regression model using the four miRNAs in both primary and
replication groups and examined their capability of separating
HNF1B-MODY from patients with other types of diabetes
(ESM Fig. 3a, b) or only from patients with HNF1A-MODY
(ESM Fig. 3c, d). In all cases it was evident that in both
cohorts the four validated miRNAs were differentially
expressed in HNF1A- and HNF1B-MODY.
Discussion
Our results show that the levels of circulating miRNAs reflect
the intracellular impact of a specific TF defect. Moreover,
miRNAs that were identified as HNF1B-associated are likely
to be involved in regulating metabolic functions associated
with renal cyst formation.
Fig. 3 Impact of HNF1α or
HNF1β knockdown on miRNA
expression levels in human
hepatocytes (HepG2). (a)
Western blot analysis of siRNA-
induced knockdown efficiency
for HNF1α. (b) Western blot
analysis of siRNA-induced
knockdown efficiency for
HNF1β. (c) mRNA expression
levels of HNF1A and HNF1B
after siRNA-induced gene
silencing. (d) miRNA expression
levels in HepG2 cells after mock
nucleofection (leftmost columns
in each block) after knockdown of
HNF1α (middle columns) and
HNF1β (rightmost columns). (e)
miRNA expression levels
measured in cell culture media
after mock nucleofection (control
group, dark grey) or HNF1β
silencing (light grey); miR-24
was not detectable). Brackets are
used to connect the groups with
significant (p< 0.05) pairwise
differences. AU, arbitrary units
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That fact that miRNAs play an important part in the
pathogenesis of diabetes is well established. Non-specific
reduction of miRNA expression inhibits the formation of beta
cells [25]. However, the question we addressed is whether
specific miRNAs are linked to specific genetic causes of
monogenic diabetes. An earlier study of miRNAs in
Fig. 4 Biological targets of HNF1β-dependent miRNAs detectable in
serum. (a) Venn diagram of genes with 3′UTR (untranslated region) frag-
ments validated to be binding sites for the four miRNAs (according to the
miRWalk database; ESM Table 6). (b) Enrichment plot from gene-set
enrichment analysis showing the relative position of genes validated as
targets of HNF1β-dependent miRNAs within the whole list of differen-
tially regulated genes observed in the HNF1β knockdown gene expres-
sion experiment [9]. Green line, enrichment profile; vertical black lines,
hits; grey lines and shading, ranking metric scores. The ranked list metric
is shown as the signal-to-noise ratio. (c) Hierarchical clustering plot of
gene expression. The first four samples are HNF1β knockdowns. (d)
Schematic representation of the HNF1α and HNF1β binding sites locat-
ed within the promoter regions of the four tested miRNAs. miR-27b and
miR-24 are clustered together. Box sizes are not to scale. sh, Short hairpin
Table 2 Diagnostic efficacy of the evaluated miRNAs withHNF1B-MODY-dependent expression profile in the validation (UK) group. Cut-off values are
ΔCts calculated as listed in theMethods section. The last two columns represent the performance of the selectedmiRNAs in the primary group of Polish patients
Evaluated
miRNA
Best cut-off value in
the replication group
AUC (95% CI) Sensitivity/specificity for
best cut-off value (%)
AUC (95% CI) separating
HNF1B- from HNF1A-MODY
Sensitivity/specificity for best
cut-off value separating HNF1B-
from HNF1A-MODY (%)
miR-24 <−0.97 0.86 (0.73, 0.99) 91.7 / 80.0 0.82 (0.66, 0.98) 91.7 / 72.2
miR-223 <1.57 0.79 (0.65, 0.92) 83.3 / 72.5 0.75 (0.56, 0.93) 83.3 / 66.7
miR-27b <−2.77 0.83 (0.70, 0.96) 83.3 / 72.5 0.84 (0.70, 0.99) 83.3 / 77.8
miR-199a <−5.07 0.82 (0.66, 0.97) 83.3 / 82.1 0.84 (0.67, 1.00) 83.3 / 88.2
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monogenic diabetes caused by HNF1A mutations was
performed by Bonner et al [26], who identified miRNAs
linked to HNF1α knockdown in the insulin-1 cell model,
and afterwards screened patients’ sera for those miRNAs.
Our report partially confirms their findings, as we found
serummiR-103 levels to be higher in theHNF1A-MODYgroup
than in the controls and HNF1B-MODY groups, although the
difference was not significant (p=0.09; ESM Table 3).
We considered the possibility that at least some circulating
miRNAs could originate from beta cells and reflect the re-
maining beta cell mass. However, given that none of the
miRNAs tested in the primary group showed simultaneously
significant differences between type 1 diabetes and GCK-
MODY and between type 1 diabetes and control groups
(ESM Table 3) we assumed that beta cells were not a likely
source of the dysregulated miRNAs. Our assumption of
extrapancreatic origin of MODY-associated miRNAs is fur-
ther strengthened by a recent report by Latreille et al, who
showed that beta cell secretion of miR-375 does not contribute
significantly to its serum levels and does not differ between
HNF1A-MODYand type 1 or type 2 diabetes [27]. Similarly,
in our study the levels of miR-375 remained unaltered in both
groups, confirming that the serum levels of this miRNA are
probably not a good indicator of beta cell mass or function.
HNF1β is typically associated with pancreatic develop-
ment [28], but high levels are also found in pancreatic
islets, kidneys, gut and liver [29]. We thus examined
HNF1β-deficient HepG2 human cell lines to investigate the
link between HNF1α/HNF1β and miRNA expression.
Silencing of HNF1B in human hepatocytes significantly
decreased intracellular levels of miR-24, miR-27b, miR-199a
and miR-223. Moreover, the reduced levels of these miRNAs
were also found in the HepG2 culture media, indicating that
extracellular transport of miRNA was also affected. Our
observations do not negate the possibility that some miRNAs
are associated with type 1 diabetes [30] and potentially with
beta cell function [31], but rather show that the serum levels of
miRNAs are probably a result of extrapancreatic effects, such
as those presented in our hepatocyte experiment.
Interestingly, another study also showed that miR-223 and
miR-199a are dependent on liver function [32], supporting our
assumption that the most significant impact of an HNF1A or
HNF1B defect would be manifested predominantly via
hepatic function disruption rather than by beta cell-associated
effects.
Linking miRNA and effector pathways in our study was
based on bioinformatic predictions; however, a recent study
on chromatin immunoprecipitation (ChIP) of HNF1β pub-
lished by Hajarnis et al (deposited as GSE71250 in the Gene
Expression Omnibus database) showed that miR-223 indeed
has a strong HNF1β-binding site in its promoter region, while
the intragenic miR-199a has an HNF1β-binding site in the
promoter of the dmm-2 gene [33]. For miR-27b and miR-24,
a ChIP signal peak was also located upstream of the miRNA
cluster. Human and mouse miRNAs show 100% homology of
their seed region sequences, making both the bioinformatics
prediction and ChIP data relevant to human data. Therefore,
while it is possible that different regulatory mechanisms
would determine miRNA expression in humans, it is very
likely that the four miRNAs are regulated directly by HNF1β.
Our study does have several limitations linked mostly to
the relative rarity of monogenic diabetes and specific recruit-
ment protocols used in both participating countries. Since in
Poland genetic screening for monogenic diabetes is performed
predominantly from the paediatric diabetology perspective we
rarely encounter a situation in which differentiation between
type 2 and monogenic diabetes is an actual issue [4]. In our
primary group, none of the MODY patients was obese,
whereas in the UK one single patient with HNF1B-MODY
crossed the 30 kg/m2 threshold of BMI. We therefore did not
consider it feasible to include patients with type 2 diabetes, as
comparison of miRNA profiles with such patients would be
heavily confounded by age, BMI and treatment modality
differences.
Second, treatment modalities or renal function variables
could also be thought of as potential confounders. None of
the patients in theHNF1B-MODY group had creatinine levels
above 115 μmol/l, and none of the patients from other groups
reported any symptoms concerning the urinary tract.
However, it is possible that in patients with a longer duration
of the disease, particularly HNF1B-MODY, renal insuffi-
ciency might play a role in shaping the miRNA transcrip-
tion profile. Similarly we did not observe any differences
in miRNA profiles in the MODY subgroups depending on
treatment (data not shown), but this was most likely due to
low statistical power.
Finally, the siRNA-induced suppression of HNF1A and
HNF1B expression in the HepG2 cell line was lower than
typically presented in knockdown studies (~60%). However,
since homozygous mutations of HNF1B are lethal [34], we
did not strive to suppress HNF1B completely and were satis-
fied with the ~60% suppression, which we deemed a situation
similar to the heterozygous loss of HNF1A or HNF1B
observed in our patients.
Monogenic diseases caused by loss of function of specific
miRNAs were reported in haematology, where a miR-451-
regulated locus is crucial for erythropoiesis [35]. An even
more extreme example is auditory loss due to a single domi-
nant point mutation of miR-96 [36]. Redundancy of miRNA
targets protects against loss of a single miRNA, but some
genes are uniquely regulated by only one miRNA, making
single-miRNA diseases possible [37]. Whether point muta-
tions of miRNA genes may be the next group of causative
factors for monogenic diabetes requires further study.
In conclusion, we have shown that expression of the
circulating miRNAs miR-24, miR-223, miR-27b and
Diabetologia (2016) 59:1463–1473 1471
miR-199a depends on HNF1β function, making them
potentially applicable in the diagnosis of HNF1B-MODY.
The impact of HNF1β deficiency was also evidenced at
cellular level, suggesting that these miRNAs may play a
functional role in shaping the HNF1B-MODYphenotype.
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